RXST Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

5.740

Open

5.500

VWAP

5.39

Vol

2.43M

Mkt Cap

232.65M

Low

4.805

Amount

13.11M

EV/EBITDA(TTM)

--

Total Shares

41.40M

EV

14.03M

EV/OCF(TTM)

--

P/S(TTM)

1.80

RxSight, Inc. is a commercial-stage medical technology company engaged in providing customized vision to patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is composed of RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and related accessories. The LAL is an intraocular lens (IOL) made from the silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (UV) light patterns generated by the LDD. Its LAL uses a silicone formulation that enables changing the mechanical and optical properties of the lens following implantation. The LDD uses software and algorithms to deliver a short UV light exposure treatment that polymerizes specific portions of the lens and allows doctors to adjust spherical and cylindrical refraction.

Show More

Events Timeline

(ET)

2026-07-07

16:00:00

RxSight Adjusts FY26 Revenue Outlook to $129.24M

2026-07-07

16:00:00

RxSight Expects Q2 2026 Revenue of $5M to $7M

2026-07-06 (ET)

2026-07-06

16:30:00

Alcon and RxSight Collaborate to Develop Adjustable Intraocular Lenses

2026-07-06

16:30:00

Alcon and RxSight Announce Collaboration to Develop Adjustable IOLs

2026-05-06 (ET)

2026-05-06

17:00:00

Company Confirms FY26 Gross Margin View at 70%-72%

2026-05-06

17:00:00

RxSight Reports Q1 Revenue of $30.89M, Beating Consensus

News

Newsfilter

07-06Newsfilter

PinnedRxSight Announces Preliminary Q2 2026 Financial Results and Product Pipeline Updates

seekingalpha

07-07seekingalpha

RxSight Q2 2026 Earnings Call Insights

NASDAQ.COM

07-07NASDAQ.COM

RxSight Reports Q2 2026 Preliminary Results and Updates Guidance

NASDAQ.COM

07-07NASDAQ.COM

Alcon Partners with RxSight to Develop Adjustable Intraocular Lenses

seekingalpha

07-06seekingalpha

Alcon and RxSight Collaborate on Adjustable Intraocular Lenses Development

seekingalpha

07-06seekingalpha

RxSight Updates 2026 Revenue Outlook Amid Q2 Preliminary Results

9 Analyst Rating

Wall Street analysts forecast RXST stock price to rise

1 Buy

6 Hold

2 Sell

Hold

Current: 0.000

Low

8.00

Averages

10.25

High

14.00

Current: 0.000

Low

8.00

Averages

10.25

High

14.00

Jefferies

Hold

downgrade

AI Analysis

2026-07-07

New

Reason

Jefferies

Price Target

AI Analysis

2026-07-07

New

downgrade

Hold

Reason

Jefferies lowered the firm's price target on RxSight to $6.50 from $7.50 and keeps a Hold rating on the shares. Q2 preliminary results missed due to competitive trialing and macro pressures, as the company expects the trailing pressures to continue and lowered guidance by about 10% for the year, or an implied roughly 18% for H2, the analyst tells investors in a research note. The firm added that monthly utilization was the lowest it's been in four years, with implied H2 utilization down roughly 10% year-over-year.

BofA

BofA

Underperform

downgrade

$8

2026-07-07

New

Reason

BofA

BofA

Price Target

$8

2026-07-07

New

downgrade

Underperform

Reason

BofA lowered the firm's price target on RxSight to $6.50 from $8 and keeps an Underperform rating on the shares. The firm notes the company pre-announced preliminary Q2 sales of $27M vs Street of $32M and lowered 2026 guidance by $13M at midpoint. RxSight pointed to elevated levels of competitive trialing and lower consumer sentiment. The company also announced a strategic collaboration with ALC to develop and commercialize light-adjustable PCIOLs using RxSight's LAL technology. The partnership allows RxSight to leverage its technology in an area it doesn't participate in today, but the path for the collaboration products will likely take a few years, argues BofA.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RXST

Unlock Now

Valuation Metrics

The current forward P/E ratio for Rxsight Inc (RXST.O) is 116.28, compared to its 5-year average forward P/E of -10.12. For a more detailed relative valuation and DCF analysis to assess Rxsight Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-10.12

Current PE

116.28

Overvalued PE

47.73

Undervalued PE

-67.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-24.44

Current EV/EBITDA

-2.71

Overvalued EV/EBITDA

4.28

Undervalued EV/EBITDA

-53.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

7.46

Current PS

1.55

Overvalued PS

11.33

Undervalued PS

3.60

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks with low shares available to short

Intellectia · 43 candidates

Region: USRelative Vol: >= 1.50Short Ratio: LessThan10PctList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Comcast Corp

86.52B

Universe Pharmaceuticals Inc

1.67M

Dynatrace, Inc

12.89B

Viridian Therapeutics Inc

2.07B

InflaRx NV

282.80M

Bgc Group Inc

5.49B

list of stocks beat suited for sell put

Intellectia · 13 candidates

Relative Vol: >= 1.50Current Ratio: >= 1.50Debt Equity: <= 0.500Weekly Average Turnover: >= 2,000,000Is Optionable: TrueOption Sentiments: Bullish

Ticker

Name

Market Cap$

OR Royalties Inc

8.14B

Gentex Corp

5.20B

CG Oncology Inc

4.61B

Sprott Inc

3.27B

Photronics Inc

2.14B

United States Antimony Corp

1.28B

show me these stocks

Intellectia · 24 candidates

Price: $0.05 - $20.00Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000Shares Outstanding: <= 50,000,000

Ticker

Name

Market Cap$

Kornit Digital Ltd

649.13M

Fuelcell Energy Inc

446.34M

Rxsight Inc

409.11M

Protara Therapeutics Inc

309.20M

One Stop Systems Inc

286.10M

Methode Electronics Inc

267.33M

I mean the lowest priced stock

Intellectia · 24 candidates

Price: <= $10.00Relative Vol: >= 1.50Gap Pattern: GapDownMoving Average Relationship: PriceCrossAboveMA5Candlestick Pattern: InverseHeadAndShoulder, WhiteCandlestick

Ticker

Name

Market Cap$

Rxsight Inc

409.11M

So-Young International Inc

305.89M

OmniAb Inc

289.35M

Funko Inc

211.27M

Namib Minerals

121.31M

Marygold Companies Inc

53.85M

What stock to buy for short term?

Intellectia · 28 candidates

Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000Rsi 14: 40 - 60Week Price Change Pct: >= $2.00

Ticker

Name

Market Cap$

Arm Holdings PLC

120.87B

Nu Holdings Ltd

83.54B

Moog Inc

9.94B

GameStop Corp

9.72B

Quantumscape Corp

6.64B

Transportadora de Gas del Sur SA

4.61B

Whales Holding RXST

No Street GP LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Rxsight Inc (RXST) stock price today?

The current price of RXST is 5.62 USD — it has increased 0.36

What is Rxsight Inc (RXST)'s business?

RxSight, Inc. is a commercial-stage medical technology company engaged in providing customized vision to patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is composed of RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and related accessories. The LAL is an intraocular lens (IOL) made from the silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (UV) light patterns generated by the LDD. Its LAL uses a silicone formulation that enables changing the mechanical and optical properties of the lens following implantation. The LDD uses software and algorithms to deliver a short UV light exposure treatment that polymerizes specific portions of the lens and allows doctors to adjust spherical and cylindrical refraction.

What is the price predicton of RXST Stock?

Wall Street analysts forecast RXST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is10.25 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Rxsight Inc (RXST)'s revenue for the last quarter?

Rxsight Inc revenue for the last quarter amounts to 30.89M USD, decreased -18.48

What is Rxsight Inc (RXST)'s earnings per share (EPS) for the last quarter?

Rxsight Inc. EPS for the last quarter amounts to -0.38 USD, increased 90.00

How many employees does Rxsight Inc (RXST). have?

Rxsight Inc (RXST) has 461 emplpoyees as of July 08 2026.

What is Rxsight Inc (RXST) market cap?

Today RXST has the market capitalization of 232.65M USD.